阿托伐他汀与瑞舒伐他汀治疗2型糖尿病合并血脂代谢异常的疗效Meta分析  

Meta-analysis of the efficacy between atorvastatin and rosuvastatin in treating type 2 diabetes mellitus patients with dyslipidemia

作　　者：陈熹 张柳婧[1] 董远[1] 徐春梅[1] 车菲 王晓东 李玉洁[2] CHEN Xi;ZHANG Liujing;DONG Yuan;XU Chunmei;CHE Fei;WANG Xiaodong;LI Yujie(Department of Traditional Chinese Pharmacy, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050,China;Institute of Chinese Medicine, Chinese Academy of Traditional Chinese Medicine, Beijing 100700,China)

机构地区：[1]首都医科大学附属北京友谊医院中药剂科,北京100050 [2]中国中医科学院中药研究所,北京100700

出　　处：《中国现代医生》2018年第11期104-107,110,共5页China Modern Doctor

基　　金：国家自然科学基金项目(81673640)

摘　　要：目的采用Meta分析的方法系统评价阿托伐他汀与瑞舒伐他汀治疗2型糖尿病合并血脂代谢异常患者的疗效对比。方法通过检索CNKI、万方数据库、VIP、CBM及Pub Med数据库,收集阿托伐他汀与瑞舒伐他汀治疗2型糖尿病合并血脂代谢异常的随机对照试验,采用RevMan 5.3软件进行Meta分析。结果共纳入文献7篇,累计患者1034例。Meta分析结果显示,瑞舒伐他汀下调低密度脂蛋白、甘油三酯、总胆固醇和C反应蛋白水平药效优于阿托伐他汀(P<0.01)。结论瑞舒伐他汀改善2型糖尿病合并血脂代谢异常患者相关指标优于阿托伐他汀。Objective To systematically evaluate the efficacy between atorvastatin and rosuvastatin in the treatment of type 2 diabetes mellitus patients with dyslipidemia by Meta-analysis. Methods Randomized controlled trials of atorvastatin and rosuvastatin in the treatment of type 2 diabetes patients with dyslipidemia were collected by searching CNKI,Wanfang database, VIP, CBM and Pub Med databases. Meta-analysis was performed using Rev Man 5.3 software. Results A total of 7 articles were included, with a total of 1034 patients. Meta-analysis showed that the effect of rosuvastatin in down-regulating low-density lipoprotein, triglyceride, total cholesterol and C-reactive protein levels is better than that of atorvastatin（P〈0.01）. Conclusion Rosuvastatin is better than atorvastatin in improving the indexes of patients with type 2 diabetes mellitus complicated with dyslipidemia.

关 键 词：阿托伐他汀 瑞舒伐他汀 2型糖尿病 血脂代谢异常 META分析 

分 类 号：R972.6[医药卫生—药品]